1 / 18

Business Meeting IG Infection & Allergy Monday 18 th June 2012

Business Meeting IG Infection & Allergy Monday 18 th June 2012. Agenda Lecture: "Clinical relevance of superantigens in allergic disease. Task force conclusions". Professor Philippe Gevaert, Chair of the Task Force on Superantigens. IG board and membership I&A sessions at EAACI 2012

marvin-holcomb
Download Presentation

Business Meeting IG Infection & Allergy Monday 18 th June 2012

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Business Meeting IG Infection & AllergyMonday 18th June 2012 Agenda Lecture: "Clinical relevance of superantigens in allergic disease. Task force conclusions".Professor Philippe Gevaert, Chair of the Task Force on Superantigens. IG board and membership I&A sessions at EAACI 2012 I&A Allergy School Edinburgh Influenza vaccination in allergy – questionnaire Influenza summit Brussels New I&A task force – suggestions please

  2. Board 2011-2013 Chairperson Jürgen SchwarzeUnited Kingdom jurgen.schwarze@ed.ac.uk • Secretary Chrysanthi SkevakiGreece cskevaki@allergy.gr • Members Carsten Flohr carsten.flohr@kcl.ac.uk Philippe Gevaertphilippe.gevaert@UGent.be • JMA Affiliate Heidi Makrinioti heidimakrinioti@gmail.com • Webmaster Chrysanthi Skevaki cskevaki@allergy.gr

  3. Membership (2010-2012)

  4. I&A Sessions at EAACI 2012 Oral abstract sessions Sunday, 17 June 201210:30 - 12:00 "Role of infections in chronic inflammation" Tuesday, 19 June 201215:30 - 17:00 "Interplay between infections and allergy"

  5. Saturday, 16 June 201214:00 - 15:30From Innate immunity to allergyIntestinal microbiota and allergic immune response, Charles Mackay, AustraliaSunday, 17 June 201213:30 - 15:00SymposiumNovel epidemiological insights on asthma and infectionRespiratory virus in the inception of childhood asthma, Robert Lemanske, United StatesRole of rhinovirus C in childhood asthma, Peter Le Souef, AustraliaBacterial colonisation as a risk factor for initiation and expression, Hans Bisgaard, Denmark15:30 - 17:00SymposiumHow can anti-infective drugs influence allergic disease?Antivirals, Peter Openshaw, United KingdomAntibiotics, Thibaut van Zele, BelgiumAntiparasitics, Maria Yazdanbakhsh, The Netherlands15:30 - 17:00SymposiumMicrobiota, nutrition and allergic diseasesProbiotics and prebiotics for the prevention and treatment, Matthias Kopp, Germany15:30 - 17:00JMA Scientific SymposiumBronchiolitis and the infant immune system, Maggina Paraskevi, Greece

  6. Monday, 18 June 201207:00 - 07:45Meet the ExpertsMeet the Expert 15 - Vaccinations in allergic children, Christoph Gruber, Germany09:00 - 10:30Plenary Symposium 4Revisiting the origins of allergyHow does the microenvironment shape the allergic response?, Stephen Holgate, United Kingdom10:45 - 12:15symposiumUnderstanding urticariaGerms and worms in urticaria, Peter Schmid-Grendelmeier, Switzerland13:30 - 15:00Business Meeting Interest Group Infections & AllergyClinical relevance of superantigens in allergic disease.  Task force conclusions, Philippe Gevaert, Belgium15:30 - 17:00SymposiumViral mechanisms in airway inflammation Innate immune mechanisms in viral bronchiolitis - from mouse to infant, Riny Janssen, The NetherlandsInterferon response in virus-induced asthma, Sebastian Johnston, united KingdomViral and bacterial interactions: their role in driving airway inflammation, Chrysanthi Skevaki, Greece15:30 - 17:00SymposiumEAACI meets RussiaThe interaction of RSV and epithelial cells in the lung, Musa Khaitov, Russia

  7. Tuesday, 19 June 201208:30 - 10:00Meet the Expert 21Environmental pressure on epigenetic changes, William Cookson, United Kingdom13:00 - 13:30Pro & Con 6Probiotics and prebiotics can reduces the incidence of infantile eczema, Pro: Philippe Eigenmann, SwitzerlandCon: Matthias Kopp, Germany15:30 - 17:00Business MeetingAsthma SectionAsthma exacerbation, Sebastian Johnston15:30 - 17:00Business MeetingPediatrics SectionPrebiotics and probiotics in allergy prevention and treatment: true or false?, Hania Szajewska, PolandWednesday, 20 June 201208:30 - 10:00Plenary Symposium 7Risk factors for allergyInfections at the inception of allergy, Nikos Papadopoulos, Greece10:30 - 12:00SymposiumMolecular profiling of allergy and inflammationImmunoproteomics: inflammatory response to staphylococcal superantigens, Barbara Broker,

  8. Clinical Impact and Mechanisms of Infections in Allergy 15 – 18 September 2011 Edinburgh, UK 8

  9. Clinical impact and mechanisms of infections in allergy15 – 18 September 2011Edinburgh, UK ALLERGY SCHOOLS 2011 13 CME credits Local organizer: Jürgen Schwarze 9

  10. Influenza vaccination in allergyquestionnaire • 241 respondents • 60% allergists, 30% paediatricians • The majority of participants (82%) advocate their patients to become vaccinated • Half of participants have been involved in influenza immunization programmes • IFV immunization of asthmatic/allergic patients is largely performed by GPs and pediatricians

  11. Resources for influenza vaccination campaignsare little or not adequate at all Half of participants have been involved in influenza immunization programmes EAACI I&A IG Survey 2012

  12. Half of physicians feel that the level of awareness among asthmatics is little or not satisfactory at all EAACI I&A IG Survey 2012

  13. The majority estimates <40% vaccination coverage of their patients What is the vaccination rate of your asthmatic patients? Similarly, low estimates for asthma patients with egg allergy EAACI I&A IG Survey 2012

  14. Declination of vaccination is strongly affected by a number of misconceptions What are the reasons, beliefs, attitudes affecting declination rates among allergic individuals? Education on vaccine efficacy/safety should be one of the priority public health measures taken EAACI I&A IG Survey 2012

  15. Half of respondents report vaccination rates <60% among physicians EAACI I&A IG Survey 2012

  16. Additional resources are needed for vaccination campaigns. The level of influenza awareness among patients with asthma should be enhanced. Vaccination rate of asthmatic patients remains low despite recommendations by their physicians. Declination of vaccination among allergic individuals is affected by misconceptions, which may be cleared up with suitable education. Conclusions

  17. 2nd ESWI Flu Summit • Network of Partner Organizations: European Public Health Alliance, International Diabetes Federation-EU, WHO-EU, ESPID, EAP, EAACI, WONCA-EU, ELF, ERS, EMA, EUGMS, EUREGHA, National Influenza Vaccine Summit, PGEU • Showcase successful projects that raised patients’ awareness • ~100 representatives of health care providers, senior citizens, at-risk patients and public health authorities: platform to expand efforts, exchange practices and initiate concrete actions, influenza challenges ahead • WHO Europe (respir path progr), EC Directorate-General for Health and Consumers, ESWI Chair & Vice-Chair, EMA, American Medical Association, ESPID, Pharmacy Union, EUGMS, Turkish Ministry of Health

  18. Task Force: “Influenza in asthma” Reported prevalence of influenza in AAE among children & adults Influenza attributable health care utilization Vaccine Effectiveness (CS intake) Vaccine Efficacy Vaccine Safety Selection of vaccine: TIV vs LAIV Compliance of asthmatics to current vaccine recommendations 18

More Related